SNY: Japan Approves Wayrilz
Sanofi's Wayrilz is approved in Japan for persistent or chronic immune thrombocytopenia based on the LUNA 3 Phase 3 study
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.